171 related articles for article (PubMed ID: 33214084)
1. Expression of genes that regulate follicle development and maturation during ovarian stimulation in poor responders.
Vaitsopoulou CI; Kolibianakis EM; Bosdou JK; Neofytou E; Lymperi S; Makedos A; Savvaidou D; Chatzimeletiou K; Grimbizis GF; Lambropoulos A; Tarlatzis BC
Reprod Biomed Online; 2021 Jan; 42(1):248-259. PubMed ID: 33214084
[TBL] [Abstract][Full Text] [Related]
2. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
3. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzis BC; Tournaye H; Devroey P
Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
[TBL] [Abstract][Full Text] [Related]
4. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
[TBL] [Abstract][Full Text] [Related]
5. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.
Huber M; Hadziosmanovic N; Berglund L; Holte J
Fertil Steril; 2013 Nov; 100(5):1270-6. PubMed ID: 23931964
[TBL] [Abstract][Full Text] [Related]
6. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
7. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
8. Controlled ovarian stimulation using a long gonadotropin-releasing hormone antagonist protocol: a proof of concept and feasibility study.
Weissman A; Ravhon A; Steinfeld Z; Nahum H; Golan A; Levran D
Gynecol Obstet Invest; 2013; 76(2):113-8. PubMed ID: 23920048
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
Wang Y; Kuang Y; Chen Q; Cai R
Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
[TBL] [Abstract][Full Text] [Related]
10. GnRHa flare and IVF pregnancy rates.
Confino E; Zhang X; Kazer RR
Int J Gynaecol Obstet; 2004 Apr; 85(1):36-9. PubMed ID: 15050465
[TBL] [Abstract][Full Text] [Related]
11. In vitro fertilization stimulation protocol for normal responder patients.
Marci R; Caserta D; Lisi F; Graziano A; Soave I; Lo Monte G; Patella A; Moscarini M
Gynecol Endocrinol; 2013 Feb; 29(2):109-12. PubMed ID: 22943624
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of nuclear progestin receptor (Pgr) and subfertility in double knockouts of progestin receptor membrane component 1 (pgrmc1) and pgrmc2 in zebrafish.
Wu XJ; Zhu Y
Gen Comp Endocrinol; 2020 Jan; 285():113275. PubMed ID: 31536721
[TBL] [Abstract][Full Text] [Related]
13. The effect of intra-ovarian androgen priming on ovarian reserve parameters in Bologna poor responders.
Vuong LN; Ho TM; Ha AN; Pham TD; Le TTN; Yding Andersen C; Humaidan P
Reprod Biomed Online; 2020 Feb; 40(2):223-228. PubMed ID: 31974029
[TBL] [Abstract][Full Text] [Related]
14. [Protocol of GNRH antagonist in poor responders in IVF-ET cycles].
Grzechocińska B; Fracki S; Marianowski P; Dworniak T; Bablok L; Marianowski L
Ginekol Pol; 2003 Sep; 74(9):943-8. PubMed ID: 14674149
[TBL] [Abstract][Full Text] [Related]
15. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
[TBL] [Abstract][Full Text] [Related]
16. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
17. The relationship between follicle development and progesterone receptor membrane component-1 expression in women undergoing in vitro fertilization.
Elassar A; Liu X; Scranton V; Wu CA; Peluso JJ
Fertil Steril; 2012 Mar; 97(3):572-8. PubMed ID: 22245528
[TBL] [Abstract][Full Text] [Related]
18. Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles.
Koo YA; Lee B; Park HJ; Choi J; Lee E; Choi D
Fertil Steril; 2009 Mar; 91(3):744-8. PubMed ID: 18321491
[TBL] [Abstract][Full Text] [Related]
19. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
[TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count.
Jayaprakasan K; Hopkisson J; Campbell B; Johnson I; Thornton J; Raine-Fenning N
BJOG; 2010 Jun; 117(7):853-62. PubMed ID: 20353458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
